147770-06-7

Basic information

• Product Name: (+)-2-Ethoxy-4-(N-3-Methyl-1(S)-(2-(1-Piperidinyl)Phenyl)-Butyl)Carbamoylmethyl)
• Synonyms: (+)-2-Ethoxy-4-(N-3-Methyl-1(S)-(2-(1-Piperidinyl)Phenyl)-Butyl)Carbamoylmethyl);(+)-2-ETHOXY-4-(N-3-METHYL-1(S)-(2-(1-PEPERIDINYL)PHENYL)-BUTYL)CARBAMOYLMETHYL) BENZOIC ACID;(S)-Ethyl 2-ethoxy-4-[[[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]amino]carbonyl]methyl]benzoate;(S)-Repaglinide Ethyl Ether (Repaglinide Impurity);2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid Ethyl Ester;(S)-Repaglinide Ethyl Ester (Repaglinide Impurity);(S)-2-Ethoxy-4-[[[N-[1-(2-piperidinopheny;(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-benzoicacid ethyl ester
• CAS NO: 147770-06-7
• Molecular Formula: C29H40N2O4
• Molecular Weight: 480.64
• Product Categories: Pharmaceutical material and intermeidates;Chiral Reagents;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 147770-06-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 115-118?C
• Boiling Point: 664.088°C at 760 mmHg
• Flash Point: 355.428°C
• Appearance: /
• Density: 1.093±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: -20°C Freezer
• Solubility: Chlorofrom, Methanol
• PKA: 14.79±0.46(Predicted)
• CAS DataBase Reference: (+)-2-Ethoxy-4-(N-3-Methyl-1(S)-(2-(1-Piperidinyl)Phenyl)-Butyl)Carbamoylmethyl)(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-2-Ethoxy-4-(N-3-Methyl-1(S)-(2-(1-Piperidinyl)Phenyl)-Butyl)Carbamoylmethyl)(147770-06-7)
• EPA Substance Registry System: (+)-2-Ethoxy-4-(N-3-Methyl-1(S)-(2-(1-Piperidinyl)Phenyl)-Butyl)Carbamoylmethyl)(147770-06-7)

Safety Data

• Hazardous Substances Data: 147770-06-7(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 147770-06-7 differently. You can refer to the following data:
1. Repaglinide impurity.
2. Repaglinide impurity

InChI:InChI=1/C29H40N2O4/c1-5-34-27-19-22(14-15-24(27)29(33)35-6-2)20-28(32)30-25(18-21(3)4)23-12-8-9-13-26(23)31-16-10-7-11-17-31/h8-9,12-15,19,21,25H,5-7,10-11,16-18,20H2,1-4H3,(H,30,32)/t25-/m0/s1

Upstream product

• 108175-51-5 ethyl 2-ethoxy-4-<2-<<3-methyl-1-<2-(1-piperidinyl)phenyl>butyl>amino>-2-oxoethyl>-benzoate 
• 546-68-9 titanium(IV) isopropylate 
• 147770-00-1 ethyl (Z)-2-ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-buten-1-yl)-aminocarbonylmethyl]-benzoate 
• 147770-07-8 ethyl (S)-2-hydroxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoate 
• 75-03-6 ethyl iodide 
• 799255-55-3 (S)-1-(2-piperidino-phenyl)-3-methyl-1-butyl-N-4-methoxybenzyl-ammonium L-mandelate 
• 99469-99-5 2-(3-ethoxy-4-(ethoxycarbonyl)phenyl) acetic acid 
• 799255-59-7 (S)-1-(2-piperidino-phenyl)-3-methyl-1-butyl-N-benzyl-ammonium L-mandelate 
• 6630-33-7 ortho-bromobenzaldehyde 
• 446-52-6 2-Fluorobenzaldehyde 
• 110-89-4 piperidine 
• 89-98-5 2-chloro-benzaldehyde 
• 147769-93-5 (1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butan-1-amine 
• 88709-17-5 ethyl 2-ethoxy-4-methyl-benzoate 

Downstream Products

• 135062-02-1 (S)-repaglinide 

Relevant articles and documents

Synthesis process of hypoglycemic drug repaglinide

The invention discloses a synthesis process of a hypoglycemic drug repaglinide. The process comprises the following steps: a) by using a compound II (S,S')-3-methyl-1-(2-piperidinophenyl)butylamine asa raw material, dissociating with an alkali, and directly condensing the obtained organic phase containing a compound III repigine with a compound IV 3-ethoxy-4-ethoxycarbonyl phenylacetic acid in the presence of an acylation reagent and an alkali without concentration; b) refining the compound V repaglinide ester crude product obtained after condensation by using an alkane solvent; and c) hydrolyzing in the presence of an alcohol solvent and an inorganic alkali, carrying out acidifying of post-treatment at a proper temperature, and purifying the obtained compound I repaglinide crude productby using an alcohol-water mixed solvent to obtain a repaglinide fine product. The synthesis process provided by the invention simplifies the synthesis steps, has the advantages of environmental protection, simple operation, high yield, low cost and the like, and is a repaglinide synthesis process suitable for industrial large-scale production.

Studies on diastereofacial selectivity of a chiral tert-butanesulfinimines for the preparation of (S)-3-Methyl-1-(2-piperidin-1-yl-phenyl)butylamine for the synthesis of repaglinide

A new method for the asymmetric synthesis of a series of chiral amines including (S)-3-methyl-1-(2-piperidin-1-yl-phenyl)butylamine (2a) a key intermediate to prepare antidiabetic drug repaglinide by using Ellman's reagent tert-butanesulfinamide. Diastereoselective addition of organometallic reagents to t-butanesulfinimines and followed by acidic and basic treatment. The obtained chiral amines were characterized by NMR, MS and other analytical data.

Repaglinide Substantially Free of Dimer Impurity

The present invention provides highly pure repaglinide substantially free of dimer impurity, and process for the preparation thereof. The present invention also relates to 2-ethoxy-N-[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzamide, an impurity of repaglinide, and a process for preparing and isolating thereof. The present invention further relates to pharmaceutical compositions comprising solid particles of pure repaglinide substantially free of dimer impurity or pharmaceutically acceptable salts thereof, wherein 90 volume-percent of the particles (D90) have a size of less than about 400 microns. The present invention also provides an optical resolution method of racemic 3-methyl-1-(2-piperidino-phenyl)-1-butylamine and use thereof for the preparation of repaglinide.